Skip to main content
OpenTrials

Clinical trial condition

Leukemia

Explore clinical trials studying Leukemia. Study availability and eligibility vary by location and protocol.

4,424 public trials 1,033 recruiting studies
Refine in advanced search Browse all conditions

Leukemia trial results

Completed

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia

NCT02491398

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI Ancona, Italy
  • U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno Ascoli Piceno, Italy
  • S.O.C. di Medicina Interna B - Ospedale - Cardinal Massaia di Asti Asti, Italy
  • Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi Bologna, Italy
View all 41 locations
View Trial Details
Completed

PH 2 ADI-PEG 20 Acute Myeloid Leukemia

NCT01910012

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • MD Anderson Houston, Texas, United States
  • Chang Gung Medical Foundation-Kaohsiung Kaohsiung City, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, Taiwan
  • CMUH Taichung, Taiwan
View Trial Details
Completed

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

NCT01248923

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • Arizona Clinical Research Center, Inc. Tucson, Arizona, United States
  • City of Hope Duarte, California, United States
  • Emory University, Winship Cancer Institute Atlanta, Georgia, United States
View all 13 locations
View Trial Details
Completed

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

NCT02759016

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • City of Hope Duarte, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Oregon Health and Sciences University Portland, Oregon, United States
View Trial Details
Completed

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT02264574

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Site Reference ID/Investigator# 0241 La Jolla, California, United States
  • Site Reference ID/Investigator# 0844 Fort Myers, Florida, United States
  • Site Reference ID/Investigator# 0763 West Palm Beach, Florida, United States
  • Site Reference ID/Investigator# 071 Louisville, Kentucky, United States
View all 71 locations
View Trial Details

Related conditions